Vivani Medical, Inc. stockholders' 2thought: 2026 Annual Meeting results show the approval of the 2022 Amended Plan, which increases the number of shares reserved under the plan by 11,000,000 to a total of 21,033,333 shares. Additionally, the company received regulatory approval from Bellberry in Australia to initiate a Phase 1 clinical trial of NPM-139, a semaglutide implant. Vivani Medical, Inc. is a medical technology company focused on drug delivery systems.
